ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

emicizumab

Its studies are mostly in Hemophilia A, led by 2 companies.

Drug pageEmicizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 20, 201713 company-led studies, 4 open or runningNext primary completion: Nov 19, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only123 open or runningphase 4since Nov 20, 2017Dec 2, 2015Nov 19, 2026phase 4 · NCT05181618
Sanofi11 open or runningphase 4since Nov 17, 2023Nov 17, 2023May 28, 2028phase 4 · NCT06145373

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named emicizumabINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Nov 17, 2023First study: phase 4 study in Hemophilia AFirst studyNCT06145373 · 20 planned · United States, Taiwan

Ahead

  1. May 28, 2028Primary completion: phase 4 study in Hemophilia ANCT06145373

TargetBeta

F10 →F9 →read by rule
“Coagulation factor IX and X other”ChEMBL 37, by rule

Studies

The one study Sanofi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06145373Hemophilia A · United States, Taiwan4RecruitingMay 28, 202820

How it is read

Names in the registry

  • “Emicizumab”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.